Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.75 · Revenue $1.90M · 4 analysts
Est. EPS $-0.72 · Revenue $1.90M · 4 analysts
Est. EPS $-3.25 · Revenue $6.40M · 6 analysts
Est. EPS $-0.69 · Revenue $750000.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $24.1M | — | -4.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-243.3M | +17.3% | -52.8% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +85.5% | — | +100.1% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1776.3% | — | -58.5% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -1011.7% | — | -60.1% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-370.2M | -44.1% | +6.3% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -1539.2% | — | +1.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 12.3% | +3.7% | +28.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.34x | -27.8% | -10.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $411.9M | +20.8% | -16.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.32 vs -2.86 | +19.0% | -1.11 vs -0.77 | -44.7% |
| Revenue Surprise | $24.1M vs $24.3M | -0.9% | $1.7M vs $3.7M | -54.5% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | Schroer John R. | officer: Chief Financial Officer | Common Stock | D | 3,282 | $26.37 |
| Aug 3, 2026 | Pangali Sanam | officer: Chief Legal Officer | Common Stock | D | 1,364 | $26.37 |
| Aug 3, 2026 | Hardiman Roy C. | officer: Chief Business & Strategy Ofcr | Common Stock | D | 2,692 | $26.37 |
| Aug 3, 2026 | Goldstein David M | officer: Chief Scientific Officer | Common Stock | D | 2,596 | $26.37 |
| Aug 3, 2026 | Drappa Jorn | officer: Chief Medical Officer | Common Stock | D | 2,447 | $26.37 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Martin Babler | President, Chief Executive Officer & Chairman | USD 1,205,069 | Male | 1965 | Active |
David Goldstein | Chief Scientific Officer | USD 821,186 | — | 1966 | Active |
Jorn Drappa | Chief Medical Officer & Head of Research and Development | USD 817,058 | — | 1965 | Active |
Roy C. Hardiman | Chief Business & Strategy Officer | USD 619,841 | Male | 1960 | Active |
Sanam Pangali | Chief Legal Officer & Corporate Secretary | — | Female | 1984 | Active |
John R. Schroer | Chief Financial Officer | — | Male | 1965 | Active |
Mark Bradley | Chief Development Officer | — | Male | 1966 | Active |
Kolbot By | Senior Vice President & Head of Technical Operations | — | Male | — | Active |
Philip Nunn | Senior Vice President of Pharmacology & Project Team Leader | — | Male | — | Active |
Claire Langrish | Senior Vice President & Head of Immunology and Translational Science | — | Female | — | Active |
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor conferences:
Alumis Inc. remains a late-stage biotech with no commercial product and significant risk. ALMS's value is primarily tied to envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. The recent share price crash, driven by a lupus trial failure, is significant but may not erase envudeucitinib's potential.
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases Transcript
Alumis NASDAQ: ALMS said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients with a high interferon gene signature, a subgroup it plans to emphasize in future development discussions with regulators.
Alumis said on Tuesday it plans to advance its experimental drug for a type of immunity-related condition in a smaller subset of patients, even after the treatment failed to meet the main goal of a mid-stage trial.
